Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

ELDN.US Logo

ELDN.US - Current Price

$1.91

Company Information

▼
Company Name
Eledon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US28617K1016
CIK: 0001404281
CUSIP: 28617K101
Currency: USD
Full Time Employees: 31
Phone: 949 238 8090
Website: https://eledon.com
Fiscal Year End: December
IPO Date: Sep 17, 2014
Description:

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Address:

19800 MacArthur Boulevard, Irvine, CA, United States, 92612

Directors & Officers

▼
Name Title Year Born
Dr. David-Alexandre C. Gros M.D., Ph.D. CEO & Non Independent Director 1972
Dr. Steven N. Perrin Ph.D. President, Chief Scientific Officer & Non Independent Director 1966
Mr. Paul Sean Little Chief Financial Officer 1965
Mr. John Herberger Vice President of Technical Operations NA
Mr. Bryan E. Smith J.D. General Counsel, Corporate Secretary & Chief Compliance Officer 1979
Dr. David Hovland Ph.D. Chief Regulatory Officer NA
Dr. Eliezer Katz F.A.C.S., M.D. Chief Medical Officer NA
Ms. Marina Escudero VP & Head of Clinical Operations NA

Shares Statistics

▼
Shares Outstanding: 75.03M
Shares Float: 50.86M
% Insiders: 105.50%
% Institutions: 5,595.40%
Short % Float: 8.23%

Valuation Metrics

▼
Enterprise Value: $37.13M
Trailing P/E: 0.00
Forward P/E: 5.39

Financial Highlights

▼
Market Cap: $129.81M
EBITDA: $-36.86M
Book Value: $1.52
Earnings/Share: $-1.30
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -44.22%
ROE (TTM): -95.49%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -0.21 N/A 10,000.00%
Sep 30, 2025 -0.21 -0.24 N/A 1,300.75%
Jun 30, 2025 -0.13 -0.22 N/A 4,090.91%
Mar 31, 2025 -0.08 -0.30 N/A 7,362.35%
Dec 31, 2024 -0.95 -0.33 N/A -18,943.99%
Sep 30, 2024 -0.32 -0.31 N/A -322.58%
Jun 30, 2024 -1.06 -0.30 N/A -25,333.33%
Mar 31, 2024 -0.34 -0.37 N/A 810.81%
Dec 31, 2023 -0.29 -0.39 N/A 2,564.10%
Sep 30, 2023 -0.35 -0.46 N/A 2,391.30%
Jun 30, 2023 -0.40 -0.46 N/A 1,304.35%
Mar 31, 2023 -0.75 -0.60 N/A -2,500.00%
Dec 31, 2022 -0.69 -0.70 N/A 142.86%
Sep 30, 2022 -0.73 -0.68 N/A -735.29%
Jun 30, 2022 -0.65 -0.70 N/A 714.29%
Mar 31, 2022 -0.69 -0.68 N/A -147.06%
Dec 31, 2021 -0.59 -0.75 N/A 2,133.33%
Sep 30, 2021 -0.66 -0.65 N/A -153.85%
Jun 30, 2021 -0.50 -0.57 N/A 1,228.07%
Mar 31, 2021 -0.57 -0.32 N/A -7,812.50%
Dec 31, 2020 -2.12 -1.39 N/A -5,251.80%
Sep 30, 2020 -5.51 -1.75 N/A -21,485.71%
Jun 30, 2020 -2.16 -2.97 N/A 2,727.27%
Mar 31, 2020 -3.42 -2.88 N/A -1,875.00%
Dec 31, 2019 -3.24 -4.68 N/A 3,076.92%
Sep 30, 2019 -3.96 -7.29 N/A 4,567.90%
Jun 30, 2019 -6.30 -7.65 N/A 1,764.71%
Mar 31, 2019 -9.36 -8.73 N/A -721.65%
Dec 31, 2018 -8.82 -7.20 N/A -2,250.00%
Sep 30, 2018 -6.66 -7.20 N/A 750.00%
Jun 30, 2018 -6.12 -5.58 N/A -967.74%
Mar 31, 2018 -6.48 -5.22 N/A -2,413.79%
Sep 30, 2017 -7.74 N/A N/A N/A
Jun 30, 2017 -23.76 -48.60 N/A 5,111.11%
Mar 31, 2017 -27.54 -48.60 N/A 4,333.33%
Dec 31, 2016 -27.54 -55.08 N/A 5,000.00%
Sep 30, 2016 -66.42 -68.85 N/A 352.94%
Jun 30, 2016 -97.20 -86.83 N/A -1,194.29%
Mar 31, 2016 -82.62 -81.32 N/A -159.86%
Dec 31, 2015 -79.38 -76.54 N/A -371.05%
Sep 30, 2015 -85.86 -81.40 N/A -547.91%
Jun 30, 2015 -64.80 -92.75 N/A 3,013.48%
Mar 31, 2015 -95.58 -49.81 N/A -9,188.92%
Dec 31, 2014 -45.36 -55.40 N/A 1,812.27%
Sep 30, 2014 -301.32 -58.70 N/A -41,332.20%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $20.55M $N/A $177.41M $59.27M $118.14M
2023-12-31 $4.61M $N/A $125.89M $42.48M $83.42M
2022-12-31 $56.41M $N/A $92.79M $8.61M $84.18M
2021-12-31 $84.83M $N/A $170.55M $6.55M $164.00M
2020-12-31 $114.20M $N/A $197.19M $6.59M $190.60M
2019-12-31 $8.79M $N/A $10.93M $1.47M $9.47M
2018-12-31 $12.97M $N/A $17.03M $2.53M $14.49M
2017-12-31 $17.23M $N/A $20.89M $1.44M $19.45M
2016-12-31 $23.22M $N/A $29.76M $2.90M $26.86M
2015-12-31 $24.02M $N/A $67.97M $6.25M $61.72M
2014-12-31 $105.26M $N/A $107.74M $4.24M $103.50M
2013-12-31 $31.75M $N/A $32.29M $87.55M $-55.27M
2012-12-31 $11.69M $N/A $11.96M $51.86M $-39.90M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 20, 2021 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist